Product nameAnti-Ceruloplasmin antibody
See all Ceruloplasmin primary antibodies
DescriptionRabbit polyclonal to Ceruloplasmin
Tested applicationsSuitable for: IHC-P, IHC-FoFr, IP, RIA, WB, ELISA, ICC/IFmore details
Species reactivityReacts with: Mouse, Human
Human ceruloplasmin purified from human plasma
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.01% Thimerosal (merthiolate)
Constituents: 50% Glycerol, PBS, pH 7.5
Concentration information loading...
PurityProtein G purified
Our Abpromise guarantee covers the use of ab48614 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||Use a concentration of 2 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.|
|IHC-FoFr||Use at an assay dependent concentration.|
|IP||Use at an assay dependent concentration.|
|RIA||Use at an assay dependent concentration.|
|WB||Use at an assay dependent concentration. Predicted molecular weight: 122 kDa.|
|ELISA||Use at an assay dependent concentration.|
|ICC/IF||Use at an assay dependent concentration.|
FunctionCeruloplasmin is a blue, copper-binding (6-7 atoms per molecule) glycoprotein. It has ferroxidase activity oxidizing Fe(2+) to Fe(3+) without releasing radical oxygen species. It is involved in iron transport across the cell membrane.
Tissue specificityExpressed by the liver and secreted in plasma.
Involvement in diseaseDefects in CP are the cause of aceruloplasminemia (ACERULOP) [MIM:604290]. It is an autosomal recessive disorder of iron metabolism characterized by iron accumulation in the brain as well as visceral organs. Clinical features consist of the triad of retinal degeneration, diabetes mellitus and neurological disturbances.
Note=Ceruloplasmin levels are decreased in Wilson disease, in which copper cannot be incorporated into ceruloplasmin in liver because of defects in the copper-transporting ATPase 2.
Sequence similaritiesBelongs to the multicopper oxidase family.
Contains 3 F5/8 type A domains.
Contains 6 plastocyanin-like domains.
- Information by UniProt
- CERU_HUMAN antibody
- Ceruloplasmin antibody
- CP 2 antibody
Ab48614 staining human tonsil. Staining is localized to the cytoplasm.
Left panel: with primary antibody at 2 ug/ml. Right panel: isotype control.
Sections were stained using an automated system (Dako PT Link), at room temperature. Sections were rehydrated and antigen retrieved with the Dako 3-in-1 antigen retrieval buffer, EDTA pH 9.0. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 minutes. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 minutes and detected with Dako Envision Flex amplification kit for 30 minutes. Colorimetric detection was completed with diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that for manual staining we recommend to optimize the primary antibody concentration and incubation time (overnight incubation), and amplification may be required.
Anti-Ceruloplasmin antibody (ab48614) at 1 µg/ml + Human Plasma Total Protein Lysate at 10 µg
Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 122 kDa
Observed band size: 122 + 148 kDa why is the actual band size different from the predicted?
Additional bands at: 34 kDa, 76 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 30 seconds
Ceruloplasmin contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted (148 kDa).
IHC-FoFr image of ceruloplasmin staining on mouse duodenal sections using ab48614. These sections were incubated in triton X (0.3% in 0.1% PBS) to permeabilise the cells and in 10% serum for 1h to block non-specific protein-protein interactions. The sections were then incubated with the antibody ab48614(1:200) overnight at +4°C. Specific protien binding was visualised using an Alexa 488 conjugated donkey secondary antibody (green staining). Alexa 568 conjugated secondary was used to visualise ab55027 binding to ferritin (red staining).
This product has been referenced in:
- Zanardi A et al. Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia. EMBO Mol Med 10:91-106 (2018). Read more (PubMed: 29183916) »
- Pelucchi S et al. Phenotypic heterogeneity in seven Italian cases of aceruloplasminemia. Parkinsonism Relat Disord 51:36-42 (2018). WB ; Human . Read more (PubMed: 29503155) »